Though several second-line options are accessible for the treatment of advanced soft-tissue sarcoma, there is a lack of predictive biomarkers available to support the selection of these drugs.
Trabectedin specifically targets mononuclear cell lineages (macrophages and monocytes) and ultimately could inhibit tumor angiogenesis. Moreover, trabectedin seems to induce the expression of immune-checkpoint proteins such as PD-L1. However, the predictive value of these factors remains unknown.
This poster from HTG investigates the expression of immune checkpoint genes and others as potential predictors of response to trabectedin in 139 soft-tissue sarcoma patients.
Offered Free by: HTG Molecular Diagnostics
See All Resources from: HTG Molecular Diagnostics